Eli Lilly and Company (NYSE:LLY) Stock Holdings Boosted by Eagle Wealth Strategies LLC

Eagle Wealth Strategies LLC grew its position in shares of Eli Lilly and Company (NYSE:LLY) by 1.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,079 shares of the company’s stock after acquiring an additional 39 shares during the quarter. Eli Lilly and Company accounts for approximately 2.6% of Eagle Wealth Strategies LLC’s portfolio, making the stock its 4th largest holding. Eagle Wealth Strategies LLC’s holdings in Eli Lilly and Company were worth $3,614,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Lynx Investment Advisory purchased a new position in shares of Eli Lilly and Company in the 2nd quarter worth about $32,000. LGT Financial Advisors LLC purchased a new position in shares of Eli Lilly and Company in the 2nd quarter worth about $36,000. Redmont Wealth Advisors LLC purchased a new position in shares of Eli Lilly and Company in the 1st quarter worth about $40,000. Morton Brown Family Wealth LLC boosted its holdings in shares of Eli Lilly and Company by 45.5% in the 2nd quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company’s stock worth $41,000 after buying an additional 15 shares during the last quarter. Finally, Richardson Financial Services Inc. purchased a new position in shares of Eli Lilly and Company in the 4th quarter worth about $43,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

LLY has been the topic of a number of research analyst reports. Morgan Stanley reissued an “overweight” rating and issued a $1,106.00 price target on shares of Eli Lilly and Company in a report on Tuesday, August 27th. Jefferies Financial Group boosted their price objective on Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a research note on Monday, June 24th. Bank of America boosted their price objective on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Truist Financial restated a “buy” rating and issued a $1,000.00 price objective (up from $892.00) on shares of Eli Lilly and Company in a research note on Tuesday, June 25th. Finally, Evercore ISI upgraded Eli Lilly and Company to a “hold” rating in a research note on Thursday, September 5th. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $977.35.

Eli Lilly and Company Price Performance

Shares of NYSE LLY traded up $2.30 during midday trading on Wednesday, hitting $916.02. 296,316 shares of the company’s stock were exchanged, compared to its average volume of 3,012,222. Eli Lilly and Company has a 12-month low of $547.61 and a 12-month high of $972.53. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74. The company has a market cap of $870.59 billion, a price-to-earnings ratio of 134.57, a PEG ratio of 2.78 and a beta of 0.42. The business’s fifty day moving average price is $904.41 and its two-hundred day moving average price is $850.31.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, August 8th. The company reported $3.92 EPS for the quarter, topping the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The company had revenue of $11.30 billion during the quarter, compared to analyst estimates of $9.83 billion. As a group, research analysts forecast that Eli Lilly and Company will post 16.49 EPS for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.